|
Synonyms: Example 10 [WO2014071832] | SAF-189 | SAF-189s
Compound class:
Synthetic organic
Comment: Rufutalkib is the INN for an anaplastic lymphoma kinase (ALK) inhibitor, that was included in WHO INN Proposed List 135 (July 2026). There is a structure match for a compound claimed in patent WO2014071832A1 [2]. Online resources suggest that Fochon Pharmaceutical's lead ALK and ROS proto-oncogene 1 (ROS1) kinase inhibitor SAF-189 is also named foritinib, however this is not a bona fide INN. It is likely that rufutalkib is the proposed INN for SAF-189. SAF-189 is intended as an orally bioavailable anti-tumour agent wit potential to overcome crizotinib resistance [1].
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 5-chloro-2-N-[(2R)-2,5-dimethyl-4-(1-methylpiperidin-4-yl)-2,3-dihydro-1-benzofuran-7-yl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 14054 | rufutalkib |
Synonyms ![]() |
| Example 10 [WO2014071832] | SAF-189 | SAF-189s |
Database Links ![]() |
|
| CAS Registry No. | 1609170-61-7 (source: WHO INN record) |
| GtoPdb PubChem SID | 530846882 |
| PubChem CID | 75203552 |
| Search Google for chemical match using the InChIKey | RAQWCVHUHOLULM-LJQANCHMSA-N |
| Search Google for chemicals with the same backbone | RAQWCVHUHOLULM |
| Search PubMed clinical trials | rufutalkib |
| Search PubMed titles | rufutalkib |
| Search PubMed titles/abstracts | rufutalkib |
| UniChem Compound Search for chemical match using the InChIKey | RAQWCVHUHOLULM-LJQANCHMSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | RAQWCVHUHOLULM-LJQANCHMSA-N |